Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Prediction of survival outcomes following postoperative radiotherapy after radical prostatectomy for prostate cancer.

Leufgens F, Berneking V, Vögeli TA, Kirschner-Hermanns R, Eble MJ, Pinkawa M.

Acta Oncol. 2019 Oct 9:1-7. doi: 10.1080/0284186X.2019.1675905. [Epub ahead of print]

PMID:
31596159
2.

Prognostic factors after salvage radiotherapy alone in patients with biochemical recurrence after radical prostatectomy.

Song W, Jeon HG, Sung HH, Jeong BC, Seo SI, Jeon SS, Choi HY, Lee HM.

Int J Urol. 2016 Jan;23(1):56-61. doi: 10.1111/iju.12960. Epub 2015 Oct 26.

3.

Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy.

Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW, Walsh PC.

JAMA. 2008 Jun 18;299(23):2760-9. doi: 10.1001/jama.299.23.2760.

4.

Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.

Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS, Klein EA, Kupelian PA, Roehrborn CG, Pistenmaa DA, Pacholke HD, Liauw SL, Katz MS, Leibel SA, Scardino PT, Slawin KM.

JAMA. 2004 Mar 17;291(11):1325-32.

PMID:
15026399
5.

Prostate-specific antigen doubling time subsequent to radical prostatectomy is a predictor of outcome following salvage external beam radiation therapy: a single-centre experience.

Servoll E, Sæter T, Vlatkovic L, Nesland JM, Waaler G, Axcrona K.

Scand J Urol. 2015 Jun;49(3):218-23. doi: 10.3109/21681805.2014.982168. Epub 2014 Nov 27.

PMID:
25428750
6.

Salvage radiotherapy for prostate-specific antigen relapse after radical prostatectomy for prostate cancer: a single-center experience.

Yoshida T, Nakayama M, Suzuki O, Matsuzaki K, Kobayashi Y, Takeda K, Arai Y, Kakimoto K, Nishiyama K, Nishimura K.

Jpn J Clin Oncol. 2011 Aug;41(8):1031-6. doi: 10.1093/jjco/hyr078. Epub 2011 Jun 21.

PMID:
21693484
7.

Identifying appropriate patients for early salvage radiotherapy after prostatectomy.

Karlin JD, Koontz BF, Freedland SJ, Moul JW, Grob BM, Wan W, Hagan MP, Anscher MS, Moghanaki D.

J Urol. 2013 Oct;190(4):1410-5. doi: 10.1016/j.juro.2013.04.078. Epub 2013 May 3.

PMID:
23648223
8.

Does Early Prostate Specific Antigen Doubling Time after Radical Prostatectomy, Calculated Prior to Prostate Specific Antigen Recurrence, Correlate with Prostate Cancer Outcomes? A Report from the SEARCH Database Group.

Teeter AE, Griffin K, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ.

J Urol. 2018 Mar;199(3):713-718. doi: 10.1016/j.juro.2017.08.107. Epub 2017 Sep 1.

PMID:
28870860
9.

Impact of Gleason pattern 5 including tertiary pattern 5 on outcomes of salvage treatment for biochemical recurrence in pT2-3N0M0 prostate cancer.

Taguchi S, Shiraishi K, Fukuhara H, Nakagawa K, Morikawa T, Naito A, Kakutani S, Takeshima Y, Miyazaki H, Nakagawa T, Fujimura T, Kume H, Homma Y.

Int J Clin Oncol. 2016 Oct;21(5):975-980. Epub 2016 Apr 20.

PMID:
27098807
10.

Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.

Ploussard G, Agamy MA, Alenda O, Allory Y, Mouracade P, Vordos D, Hoznek A, Abbou CC, de la Taille A, Salomon L.

BJU Int. 2011 Jun;107(11):1748-54. doi: 10.1111/j.1464-410X.2010.09728.x. Epub 2010 Sep 30.

11.

Postoperative radiation therapy for patients at high-risk of recurrence after radical prostatectomy: does timing matter?

Hsu CC, Paciorek AT, Cooperberg MR, Roach M 3rd, Hsu IC, Carroll PR.

BJU Int. 2015 Nov;116(5):713-20. doi: 10.1111/bju.13043. Epub 2015 May 26.

12.

Hypofractionated radiotherapy as salvage for rising prostate-specific antigen after radical prostatectomy.

Lee LW, McBain CA, Swindell R, Wylie JP, Cowan RA, Logue JP.

Clin Oncol (R Coll Radiol). 2004 Dec;16(8):517-22.

PMID:
15630843
13.

Salvage intensity modulated radiotherapy using endorectal balloon after radical prostatectomy: clinical outcomes.

Ishiyama H, Teh BS, Blanco AI, Paulino AC, Mai WY, Caillouet J, Xu B, Butler EB.

Int J Urol. 2013 Dec;20(12):1178-83. doi: 10.1111/iju.12145. Epub 2013 Apr 9.

14.

Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.

Carrie C, Hasbini A, de Laroche G, Richaud P, Guerif S, Latorzeff I, Supiot S, Bosset M, Lagrange JL, Beckendorf V, Lesaunier F, Dubray B, Wagner JP, N'Guyen TD, Suchaud JP, Créhange G, Barbier N, Habibian M, Ferlay C, Fourneret P, Ruffion A, Dussart S.

Lancet Oncol. 2016 Jun;17(6):747-756. doi: 10.1016/S1470-2045(16)00111-X. Epub 2016 May 6. Erratum in: Lancet Oncol. 2016 Jun;17 (6):e223. Erratum in: Lancet Oncol. 2019 Jun;20(6):e293.

PMID:
27160475
15.

Improved outcomes with higher doses for salvage radiotherapy after prostatectomy.

King CR, Spiotto MT.

Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):23-7. doi: 10.1016/j.ijrobp.2007.09.047. Epub 2008 Jan 22.

PMID:
18207668
16.

Risk factors predicting the outcome of salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy.

Kinoshita H, Shimizu Y, Mizowaki T, Takayama K, Norihisa Y, Kamoto T, Kamba T, Hayashino Y, Hiraoka M, Ogawa O.

Int J Urol. 2013 Aug;20(8):806-11. doi: 10.1111/iju.12049. Epub 2013 Jan 8.

17.

Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy.

Briganti A, Karnes RJ, Joniau S, Boorjian SA, Cozzarini C, Gandaglia G, Hinkelbein W, Haustermans K, Tombal B, Shariat S, Sun M, Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T.

Eur Urol. 2014 Sep;66(3):479-86. doi: 10.1016/j.eururo.2013.11.045. Epub 2013 Dec 12.

PMID:
24345725
18.

Outcomes of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.

Lee EK, Mui WH, Chan AW, Tung Y, Wong FC.

Hong Kong Med J. 2018 Jun;24(3):218-225. doi: 10.12809/hkmj176888. Epub 2018 May 21.

19.

The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.

Bianchi L, Nini A, Bianchi M, Gandaglia G, Fossati N, Suardi N, Moschini M, Dell'Oglio P, Schiavina R, Montorsi F, Briganti A.

Eur Urol. 2016 Jun;69(6):1142-8. doi: 10.1016/j.eururo.2015.12.010. Epub 2015 Dec 31.

PMID:
26749093
20.

Prostate cancer outcomes of men with biopsy Gleason score 6 and 7 without cribriform or intraductal carcinoma.

Kweldam CF, Kümmerlin IP, Nieboer D, Verhoef EI, Steyerberg EW, Incrocci L, Bangma CH, van der Kwast TH, Roobol MJ, van Leenders GJ.

Eur J Cancer. 2016 Oct;66:26-33. doi: 10.1016/j.ejca.2016.07.012. Epub 2016 Aug 11.

PMID:
27522247

Supplemental Content

Support Center